Long-term Outcome In Patients With Recurrent Malignant Glioma Treated With Perillyl Alcohol Inhalation | 18095
ISSN: 2155-6105

Journal of Addiction Research & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Long-term outcome in patients with recurrent malignant glioma treated with perillyl alcohol inhalation

3rd International Conference and Exhibition on Addiction Research & Therapy

Clovis O Da Fonseca, Raphael M Teixeira, Julio Cesar T Silva, Juliana Da Gama Fischer, Osorio C Meirelles, Jose Alberto Landeiro and Thereza Quirico-Santos

Accepted Abstracts: J Addict Res Ther

DOI: 10.4172/2155-6105.S1.019

Aim: This retrospective study aimed to evaluate long-term response and toxicity of recurrent malignant glioma patients to inhalation chemotherapy with perillyl alcohol (POH). Patients and methods: The cohort included 117 men and 81 women with primary glioblastoma multiforme (GBM; n=154), grade III astrocytoma (AA; n=26) and anaplastic oligodendroglioma (AO; n=5). POH inhalation schedule 4-times daily started with 66.7 mg/dose; 266 mg/day and escalated up to 133.4 mg/dose; 533.6 mg/day. Clinical toxicity and overall survival following treatment were compared with tumor size; topography; extent of peritumoral edema and histological classification. Results: Adhesion to the protocol was high (>95%), POH (533.6 mg/daily) occasionally caused nose soreness but rarely nosebleed. Tumor size, peritumoral edema and oligodendroglial component influenced response to treatment. Conclusion: After 4 years under exclusive POH treatment, 19% patients still remain in clinical remission. Long-term POH inhalation chemotherapy is a safe and non-invasive strategy efficient for recurrent malignant glioma